Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma
- Conditions
- Primary Congenital Glaucoma
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01020721
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Phase 2
Completed
- Conditions
- Chemotherapy-Induced Nausea and VomitingOvarian Cancer
- Interventions
- Drug: Aprepitant/Ramosetron/Dexamethasone
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 89
- Registration Number
- NCT01012336
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay
Not Applicable
Completed
- Conditions
- Latent Tuberculosis Infection
- Interventions
- Other: 1-step tuberculin skin test (TST) and blood sampling
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 322
- Registration Number
- NCT01007396
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma
Phase 2
Completed
- Conditions
- NK/T-cell Lymphoma of Nasal Cavity
- Interventions
- Other: CCRT followed by VIDL chemotherapy
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2019-02-07
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT01007526
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
An Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix)
Phase 4
- Conditions
- Hypertrophic Cicatrix
- Interventions
- Other: no treatmentDevice: silicone gel
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2010-12-13
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT01004536
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Kyung-Hee University Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens
Terminated
- Conditions
- Atypical MycobacteriaMycobacterium Infections
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT00999076
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin
Completed
- Conditions
- Curatively Resected Stage III Colon Cancer
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2010-04-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00977717
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study of Nontuberculous Mycobacterial Lung Disease
Recruiting
- Conditions
- Nontuberculous Mycobacterial Lung Disease
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT00970801
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 220
- Registration Number
- NCT00954889
- Locations
- 🇰🇷
Department of Urology, Samsung Medical Center, Seoul, Korea, Republic of
Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Gemcitabine+simvastatinDrug: Gemcitabine+Placebo
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 106
- Registration Number
- NCT00944463
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath